Abbott
This article was originally published in The Gray Sheet
Executive Summary
Response to FDA consent decree final inspection observations is being prepared for submission "in a timely manner" following Jan. 18 close-out meeting with FDA, VP John Thomas reports Jan. 29 at the U.S. Bancorp Piper Jaffray Health Care Conference in New York City ("The Gray Sheet" Jan. 21, 2002, p. 9). Digene notes it has re-acquired from Abbott exclusive rights to distribute Digene's chlamydia and gonorrhea (CT/GC) tests and accessories worldwide, allowing Digene to market tests for human papillomavirus, chlamydia and gonorrhea from a single specimen...